Association of Pharmacy
Technicians UK (APTUK)
The Professional Leadership Body for Pharmacy Technicians

Respiratory pathogens – especially respiratory syncytial virus (RSV), influenza and parainfluenza – seem to increase the risk of treatment failure in children with moderate or severe asthma exacerbations who need emergency treatment.

A Canadian study found that of 958 children aged from one to 17 years, 61.7 per cent tested positive for at least one respiratory pathogen – usually rhinovirus (isolated from 29.4 per cent of children). Treatment failure, which was experienced by 16.9 per cent of children, was defined as hospital admission for asthma, treatment in the emergency department lasting eight hours or more after corticosteroids, or a relapse within 72 hours of discharge that led to hospital admission or a prolonged stay in casualty.

The presence of a pathogen was not associated with asthma severity at baseline but the risk of treatment failure was significantly higher in those children infected with a respiratory pathogen than those who were not (20.7 and 12.5 per cent respectively). Nonrhinovirus pathogens, in particular, increased the risk of treatment failure by 13.1 per cent overall, and by 8.8 per cent for RSV, 24.9 per cent for influenza and 34.1 per cent for parainfluenza.

“This is the first time we have been able to disentangle the risk of non-response to asthma treatment with the presence of specific viruses – specifically, influenza and rhinovirus,” said author Caroline Quach, associate professor of microbiology and infectious diseases at Montreal University.

“The more than 20 per cent higher absolute risk of treatment failure in flu cases is very significant. Influenza is the only respiratory virus that is vaccine-preventable. Granted, it is at best only 50 per cent efficacious, but that is no reason for children with asthma not to get vaccinated yearly [in the autumn] before the flu season starts.”

(Paediatrics DOI:10.1542/ peds.2017-4105)

• Spiriva (tiotropium) Respimat is now available as an add-on maintenance bronchodilator for patients aged at least six years with severe asthma who experienced at least one severe asthma exacerbation in the past year.

Originally Published by Pharmacy Magazine

Related articles

Men’s health: An uphill struggle

At a time when we’re supposedly more health aware than ever before, what could be causing men to neglect their health?

Male fertility

This pharmacy scenario is about male fertility and considers the ways in which men can maximise their chances of conciev...

Female fertility

This pharmacy scenario is about female fertility and considers the ways in which women can maximise their chances of con...

More articles

APTUK extend ‘Supervision’ survey date

APTUK is asking Pharmacy Technicians and Pre-registration Trainee Pharmacy Technicians across Great Britain and Northern...

The Safe and Secure Handling of Medicines

A new edition of the Royal Pharmaceutical Society’s essential guide, The Safe and Secure Handling of Medicines&nbs...

APTUK open President & Vice President nominations

APTUK is seeking nominations from Pharmacy Technicians with the drive, ambition and commitment to lead the Association a...



This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Association of Pharmacy Technicians UK (APTUK)'s Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.